Regulation of an autoimmune model for multiple sclerosis in Th2-biased GATA3 transgenic mice

International Journal of Molecular Sciences

Volumn 15, Issue 2, 2014, Pages 1700-1718

  Fernando, Viromi ^a   Omura, Seiichi ^a   Sato, Fumitaka ^a   Kawai, Eiichiro ^a   Martinez, Nicholas E ^a   Elliott, Sadie Faith ^a   Yoh, Keigyou ^b   Takahashi, Satoru ^b   Tsunoda, Ikuo ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Animal models; Autoimmune demyelinating diseases; Autoimmunity; GATA3 transcription factor; Histology; Incomplete Freund's adjuvant; Luxol fast blue; Oligodendrocyte myelin glycoprotein; Paraffin; Th1 Th2 assays; Th17

Indexed keywords

CD4 ANTIBODY; CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; MITOGENIC AGENT; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUROFILAMENT PROTEIN; TRANSCRIPTION FACTOR GATA 3; CD3 ANTIGEN; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; DEMYELINATION; DISEASE SEVERITY; DNA SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALE; MENINGITIS; MOUSE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEUROPROTECTION; NONHUMAN; PROTEIN PHOSPHORYLATION; TH2 CELL; ANIMAL; DEMYELINATING DISEASE; DISEASE MODEL; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MUTATION; PATHOLOGY; SPINAL CORD; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD3; CYTOKINES; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GATA3 TRANSCRIPTION FACTOR; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; MUTATION; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; SPINAL CORD; T-LYMPHOCYTE SUBSETS; TH2 CELLS;

EID: 84892982008     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15021700     Document Type: Article

References (65)

1. Sato, F.; Omura, S.; Martinez, N.E.; Tsunoda, I. Animal Models of Multiple Sclerosis. In Neuroinflammation, 1st ed.; Minagar, A., Ed.; Elsevier Publications: London, UK, 2011; pp. 55-79.
2. Bielekova, B.; Goodwin, B.; Richert, N.; Cortese, I.; Kondo, T.; Afshar, G.; Gran, B.; Eaton, J.; Antel, J.; Frank, J.A.; et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000, 6, 1167-1175.
3. Rizvi, S.A.; Kim, E.; Moodie, J. Glatiramer in the treatment of multiple sclerosis. Int. J. Nanomed. 2006, 1, 283-289.
4. Rudick, R.A.; Stuart, W.H.; Calabresi, P.A.; Confavreux, C.; Galetta, S.L.; Radue, E.W.; Lublin, F.D.; Weinstock-Guttman, B.; Wynn, D.R.; Lynn, F.; et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354, 911-923.
5. Tsunoda, I.; Libbey, J.E.; Kuang, L.-Q.; Terry, E.J.; Fujinami, R.S. Massive apoptosis in lymphoid organs in animal models for primary and secondary progressive multiple sclerosis. Am. J. Pathol. 2005, 167, 1631-1646.
6. Martinez, N.E.; Sato, F.; Omura, S.; Minagar, A.; Alexander, J.S.; Tsunoda, I. Immunopathological patterns from EAE and Theiler's virus infection: Is multiple sclerosis a homogenous 1-stage or heterogenous 2-stage disease? Pathophysiology 2013, 20, 71-84.
7. Tsunoda, I.; Fujinami, R.S. Two models for multiple sclerosis: Experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. J. Neuropathol. Exp. Neurol. 1996, 55, 673-686.
8. Tuohy, V.K.; Sobel, R.A.; Lees, M.B. Myelin proteolipid protein-induced experimental allergic encephalomyelitis. Variations of disease expression in different strains of mice. J. Immunol. 1988, 140, 1868-1873.
9. Dyment, D.A.; Herrera, B.M.; Cader, M.Z.; Willer, C.J.; Lincoln, M.R.; Sadovnick, A.D.; Risch, N.; Ebers, G.C. Complex interactions among MHC haplotypes in multiple sclerosis: Susceptibility and resistance. Hum. Mol. Genet. 2005, 14, 2019-2026.
10. Kasper, L.H.; Shoemaker, J. Multiple sclerosis immunology: The healthy immune system vs. the MS immune system. Neurology 2010, 74, S2-S8.
11. Balabanov, R.; Strand, K.; Goswami, R.; McMahon, E.; Begolka, W.; Miller, S.D.; Popko, B. Interferon-γ-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J. Neurosci. 2007, 27, 2013-2024.
12. + T cells produce matrix metalloproteinase-9 and osteopontin in the pathogenesis of multiple sclerosis. J. Immunol. 2012, 189, 5057-5065.
13. McGeachy, M.J.; Anderton, S.M. Cytokines in the induction and resolution of experimental autoimmune encephalomyelitis. Cytokine 2005, 32, 81-84.
14. Kennedy, M.K.; Torrance, D.S.; Picha, K.S.; Mohler, K.M. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 1992, 149, 2496-2505.
15. Falcone, M.; Rajan, A.J.; Bloom, B.R.; Brosnan, C.F. A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice. J. Immunol. 1998, 160, 4822-4830.
16. Betteli, E.; Das, M.P.; Howard, E.D.; Weiner, H.L.; Sobel, R.A.; Kuchroo, V.K. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10 and IL-4 deficient and transgenic mice. J. Immunol. 1998, 161, 3299-3306.
17. Cua, D.J.; Groux, H.; Hinton, D.R.; Stohlman, S.A.; Coffman, R.L. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 1999, 189, 1005-1010.
18. Croxford, J.L.; Feldmann, M.; Chernajovsky, Y.; Baker, D. Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10: A comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. J. Immunol. 2001, 166, 4124-4130.
19. s mouse strains. Brain Pathol. 2000, 10, 402-418.
20. Tsunoda, I.; Kuang, L.-Q.; Igenge, I.Z.M.; Fujinami, R.S. Converting relapsing remitting to secondary progressive experimental allergic encephalomyelitis (EAE) by ultraviolet B irradiation. J. Neuroimmunol. 2005, 160, 122-134.
21. Lafaille, J.J.; Keere, F.V.; Hsu, A.L.; Baron, J.L.; Haas, W.; Raine, C.S.; Tonegawa, S. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 1997, 186, 307-312.
22. Krakowski, M.; Owens, T. Interferon-γ confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 1996, 26, 1641-1646.
23. Ferber, I.A.; Brocke, S.; Taylor-Edwards, C.; Ridgway, W.; Dinisco, C.; Steinman, L.; Dalton, D.; Fathman, C.G. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 1996, 156, 5-7.
24. Voorthuis, J.A.C.; Uitdehaag, B.M.J.; de Groot, C.J.A.; Goede, P.H.; van der Meide, P.H.; Dijkstra, C.D. Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats. Clin. Exp. Immunol. 1990, 81, 183-188.
25. Lees, J.R.; Golumbek, P.T.; Sim, J.; Dorsey, D.; Russell, J.H. Regional CNS responses to IFN-γ determine lesion localization patterns during EAE pathogenesis. J. Exp. Med. 2008, 205, 2633-2642.
26. Willenborg, D.O.; Fordham, S.; Bernard, C.C.; Cowden, W.B.; Ramshaw, I.A. IFN-γ plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 1996, 157, 3223-3227.
27. Willenborg, D.O.; Fordham, S.; Staykova, M.A.; Ramshaw, I.A.; Cowden, W.B. IFN-γ is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: A possible role for nitric oxide. J. Immunol. 1999, 163, 5278-5286.
28. Liu, L.; Okada, S.; Kong, X.-F.; Kreins, A.Y.; Cypowyj, S.; Abhyankar, A.; Toubiana, J.; Itan, Y.; Audry, M.; Nitschke, P.; et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 2011, 208, 1635-1648.
29. Masters, S.L.; Simon, A.; Aksentijevich, I.; Kastner, D.L. Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 2009, 27, 621-668.
30. Kimura, T.; Ishii, Y.; Yoh, K.; Morishima, Y.; Iizuka, T.; Kiwamoto, T.; Matsuno, Y.; Homma, S.; Nomura, A.; Sakamoto, T.; et al. Overexpression of the transcription factor GATA-3 enhances the development of pulmonary fibrosis. Am. J. Pathol. 2006, 169, 96-104.
31. Huber, J.P.; Ramos, H.J.; Gill, M.A.; Farrar, J.D. Cutting edge: Type I IFN reverses human Th2 commitment and stability by suppressing GATA3. J. Immunol. 2010, 185, 813-817.
32. Zheng, W.; Flavell, R.A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997, 89, 587-596.
33. Ferber, I.A.; Lee, H.-J.; Zonin, F.; Heath, V.; Mui, A.; Arai, N.; O'Garra, A. GATA-3 significantly downregulates IFN-γ production from developing Th1 cells in addition to inducing IL-4 and IL-5 levels. Clin. Immunol. 1999, 91, 134-144.
34. Ouyang, W.; Ranganath, S.H.; Weindel, K.; Bhattacharya, D.; Murphy, T.L.; Sha, W.C.; Murphy, K.M. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 1998, 9, 745-755.
35. Ho, I.; Pai, S. GATA-3-not just for Th2 cells anymore. Cell Mol. Immunol. 2007, 4, 15-29.
36. Yoh, K.; Shibuya, K.; Morito, N.; Nakano, T.; Ishizaki, K.; Shimohata, H.; Nose, M.; Izui, S.; Shibuya, A.; Koyama, A.; et al. Transgenic overexpression of GATA-3 in T lymphocytes improves autoimmune glomerulonephritis in mice with a BXSB/MpJ-Yaa genetic background. J. Am. Soc. Nephrol. 2003, 14, 2494-2502.
37. Kiwamoto, T.; Ishii, Y.; Morishima, Y.; Yoh, K.; Maeda, A.; Ishizaki, K.; Iizuka, T.; Hegab, A.E.; Matsuno, Y.; Homma, S.; et al. Transcription factors T-bet and GATA-3 regulate development of airway remodeling. Am. J. Respir. Crit. Care Med. 2006, 174, 142-151.
38. Kiwamoto, T.; Ishii, Y.; Morishima, Y.; Yoh, K.; Kikuchi, N.; Haraguchi, N.; Masuko, H.; Kawaguchi, M.; Nomura, A.; Sakamoto, T.; et al. Blockade of cysteinyl leukotriene-1 receptors suppresses airway remodelling in mice overexpressing GATA-3. Clin. Exp. Allergy 2011, 41, 116-128.
39. Tsunoda, I.; Tanaka, T.; Terry, E.J.; Fujinami, R.S. Contrasting roles for axonal degeneration in an autoimmune versus viral model of multiple sclerosis: When can axonal injury be beneficial? Am. J. Pathol. 2007, 170, 214-226.
40. Tsunoda, I.; Kuang, L.-Q.; Libbey, J.E.; Fujinami, R.S. Axonal injury heralds virus-induced demyelination. Am. J. Pathol. 2003, 162, 1259-1269.
41. Tsunoda, I.; Kuang, L.-Q.; Tolley, N.D.; Whitton, J.L.; Fujinami, R.S. Enhancement of experimental allergic encephalomyelitis (EAE) by DNA immunization with myelin proteolipid protein (PLP) plasmid DNA. J. Neuropathol. Exp. Neurol. 1998, 57, 758-767.
42. Tsunoda, I.; Lane, T.E.; Blackett, J.; Fujinami, R.S. Distinct roles for IP-10/CXCL10 in three animal models, Theiler's virus infection, EAE, and MHV infection, for multiple sclerosis: Implication of differing roles for IP-10. Mult. Scler. 2004, 10, 26-34.
43. + T cells that promptly produce interleukin 4. Proc. Natl. Acad. Sci. USA 1995, 92, 11931-11934.
44. H2 response and in immunoglobulin E production. Science 1995, 270, 1845-1847.
45. + natural killer T cells in a viral model for multiple sclerosis. J. Neurovirol. 2009, 15, 90-98.
46. Tsunoda, I.; Tanaka, T.; Fujinami, R.S. Regulatory role of CD1d in neurotropic virus infection. J. Virol. 2008, 82, 10279-10289.
47. Segal, B.M.; Shevach, E.M. IL-12 unmasks latent autoimmune disease in resistant mice. J. Exp. Med. 1996, 184, 771-775.
48. Szabo, S.J.; Jacobson, N.G.; Dighe, A.S.; Gubler, U.; Murphy, K.M. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity 1995, 2, 665-675.
49. Jäger, A.; Dardalhon, V.; Sobel, R.A.; Bettelli, E.; Kuchroo, V.K. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 2009, 183, 7169-7177.
50. Komiyama, Y.; Nakae, S.; Matsuki, T.; Nambu, A.; Ishigame, H.; Kakuta, S.; Sudo, K.; Iwakura, Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177, 566-573.
51. Karlsson, F.; Martinez, N.E.; Gray, L.; Zhang, S.; Tsunoda, I.; Grisham, M.B. Therapeutic evaluation of ex vivo-generated versus natural regulatory T-cells in a mouse model of chronic gut inflammation. Inflamm. Bowel Dis. 2013, 19, 2282-2294.
52. Martinez, N.E.; Sato, F.; Kawai, E.; Omura, S.; Chervenak, R.P.; Tsunoda, I. Regulatory T cells and Th17 cells in viral infections: Implications for multiple sclerosis and myocarditis. Future Virol. 2012, 7, 593-608.
53. Hofstetter, H.H.; Ibrahim, S.M.; Koczan, D.; Kruse, N.; Weishaupt, A.; Toyka, K.V.; Gold, R. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell. Immunol. 2005, 237, 123-130.
54. Chakravarti, S.; Sabatos, C.A.; Xiao, S.; Illes, Z.; Cha, E.K.; Sobel, R.A.; Zheng, X.X.; Strom, T.B.; Kuchroo, V.K. Tim-2 regulates T helper type 2 responses and autoimmunity. J. Exp. Med. 2005, 202, 437-444.
55. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6, 1123-1132.
56. Park, H.; Li, Z.; Yang, X.O.; Chang, S.H.; Nurieva, R.; Wang, Y.-H.; Wang, Y.; Hood, L.; Zhu, Z.; Tian, Q.; et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005, 6, 1133-1141.
57. Tsunoda, I.; Libbey, J.E.; Fujinami, R.S. TGF-β1 suppresses T cell infiltration and VP2 puff B mutation enhances apoptosis in acute polioencephalitis induced by Theiler's virus. J. Neuroimmunol. 2007, 190, 80-89.
58. Isobe, N.; Kanamori, Y.; Yonekawa, T.; Matsushita, T.; Shigeto, H.; Kawamura, N.; Kira, J. First diagnostic criteria for atopic myelitis with special reference to discrimination from myelitis-onset multiple sclerosis. J. Neurol. Sci. 2012, 316, 30-35.
59. Nakamura, Y.; Ghaffar, O.; Olivenstein, R.; Taha, R.A.; Soussi-Gounni, A.; Zhang, D.H.; Ray, A.; Hamid, Q. Gene expression of the GATA-3 transcription factor is increased in atopic asthma. J. Allergy Clin. Immunol. 1999, 103, 215-222.
60. Ano, S.; Morishima, Y.; Ishii, Y.; Yoh, K.; Yageta, Y.; Ohtsuka, S.; Matsuyama, M.; Kawaguchi, M.; Takahashi, S.; Hizawa, N. Transcription factors GATA-3 and RORγt are important for determining the phenotype of allergic airway inflammation in a murine model of asthma. J. Immunol. 2013, 190, 1056-1065.
61. Keegan, M.; König, F.; McClelland, R.; Brück, W.; Morales, Y.; Bitsch, A.; Panitch, H.; Lassmann, H.; Weinshenker, B.; Rodriguez, M.; et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005, 366, 579-582.
62. Zhumabekov, T.; Corbella, P.; Tolaini, M.; Kioussis, D. Improved version of a human CD2 minigene based vector for T cell-specific expression in transgenic mice. J. Immunol. Methods 1995, 185, 133-140.
63. Tsunoda, I.; Terry, E.J.; Marble, B.J.; Lazarides, E.; Woods, C.; Fujinami, R.S. Modulation of experimental autoimmune encephalomyelitis by VLA-2 blockade. Brain Pathol. 2007, 17, 45-55.
64. Sato, F.; Martinez, N.E.; Shahid, M.; Rose, J.W.; Carlson, N.G.; Tsunoda, I. Resveratrol exacerbates both autoimmune and viral models for multiple sclerosis. Am. J. Pathol. 2013, 183, 1390-1396.
65. + B-1 cells in EAE pathogenesis. Autoimmunity 2008, 41, 353-362.